×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:GLTO

Galecto Stock Forecast, Price & News

$1.70
-0.03 (-1.73%)
(As of 07/1/2022 08:00 PM ET)
Add
Compare
Today's Range
$1.70
$1.70
50-Day Range
$1.22
$2.35
52-Week Range
$1.17
$5.15
Volume
15,000 shs
Average Volume
94,313 shs
Market Capitalization
$42.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Galecto MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
311.8% Upside
$7.00 Price Target
Short Interest
Healthy
0.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.39mentions of Galecto in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.64) to ($2.62) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.12 out of 5 stars

Medical Sector

345th out of 1,427 stocks

Pharmaceutical Preparations Industry

162nd out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive GLTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galecto and its competitors with MarketBeat's FREE daily newsletter.

Galecto logo

About Galecto (NASDAQ:GLTO) Stock

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

GLTO Stock News Headlines

Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide.
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide.
Galecto to Participate at Upcoming Investor Conferences
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLTO
Fax
N/A
Employees
28
Year Founded
N/A

Company Calendar

Last Earnings
4/29/2022
Today
7/04/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+311.8%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-51,750,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.64 per share

Miscellaneous

Free Float
22,938,000
Market Cap
$42.95 million
Optionable
Not Optionable
Beta
0.19














Galecto Frequently Asked Questions

Should I buy or sell Galecto stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galecto in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Galecto stock.
View analyst ratings for Galecto
or view top-rated stocks.

What is Galecto's stock price forecast for 2022?

1 analysts have issued 12-month target prices for Galecto's stock. Their GLTO stock forecasts range from $7.00 to $7.00. On average, they predict Galecto's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 311.8% from the stock's current price.
View analysts' price targets for Galecto
or view top-rated stocks among Wall Street analysts.

How has Galecto's stock performed in 2022?

Galecto's stock was trading at $3.03 on January 1st, 2022. Since then, GLTO shares have decreased by 43.9% and is now trading at $1.70.
View the best growth stocks for 2022 here
.

When is Galecto's next earnings date?

Galecto is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Galecto
.

How were Galecto's earnings last quarter?

Galecto, Inc. (NASDAQ:GLTO) released its earnings results on Friday, April, 29th. The company reported ($0.67) earnings per share (EPS) for the quarter.
View Galecto's earnings history
.

Who are Galecto's key executives?

Galecto's management team includes the following people:
  • Dr. Hans T. Schambye M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 56, Pay $735.2k) (LinkedIn Profile)
  • Mr. Jonathan P. Freve CPA, CPA, Chief Financial Officer (Age 44, Pay $602.4k) (LinkedIn Profile)
  • Mr. Anders Pedersen, Chief Operating Officer (Age 62, Pay $540.39k)
  • Mr. Ulf J. Nilsson, Co-Founder
  • Dr. Hakon Leffler, Co-Founder
  • Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP, Co-Founder & Member of the Clinical Advisory Board - IPF
  • Mr. Garrett Winslow Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 43) (LinkedIn Profile)
  • Prof. Bertil Lindmark M.D., Ph.D., Chief Medical Officer (Age 67)
  • Dr. Stephanie Oestreich Ph.D., Chief Bus. Officer (Age 48)

When did Galecto IPO?

(GLTO) raised $86 million in an initial public offering (IPO) on Thursday, October 29th 2020. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and Kempen & Co. was co-manager.

What is Galecto's stock symbol?

Galecto trades on the NASDAQ under the ticker symbol "GLTO."

How do I buy shares of Galecto?

Shares of GLTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galecto's stock price today?

One share of GLTO stock can currently be purchased for approximately $1.70.

How much money does Galecto make?

Galecto (NASDAQ:GLTO) has a market capitalization of $42.95 million. The company earns $-51,750,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis.

How many employees does Galecto have?

Galecto employs 28 workers across the globe.

How can I contact Galecto?

Galecto's mailing address is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. The official website for Galecto is galecto.com. The company can be reached via phone at 45-7070-5210.

This page (NASDAQ:GLTO) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.